Saccharomyces boulardii 用于 艰难梭菌感染（CDI）
B 证据 至少一项随机试验支持这一结论，结果基本一致。荟萃分析显示，作为标准抗生素治疗的辅助手段时，布拉迪酵母菌可将CDI复发率降低50%至60%。是预防复发性CDI证据最强的干预。
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'gutcited.com';
const params = 'ingredient\u003Dsaccharomyces\u002Dboulardii\u0026condition\u003Dclostridioides\u002Ddifficile';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
B
结论
荟萃分析显示，作为标准抗生素治疗的辅助手段时，布拉迪酵母菌可将CDI复发率降低50%至60%。是预防复发性CDI证据最强的干预。
Key Study Findings
Review
The evidence for probiotics in the treatment of digestive disorders in the pediatric population.
Dose: None
vs: None
Outcome: None
效果: None
None
研究人群: Pediatric population
Review
Clostridioides difficile Infections: Prevention and Treatment Strategies.
Dose: None
vs: None
Outcome: C. difficile infection treatment outcomes
效果: None
None
研究人群: Patients with C. difficile infection
Review
520 weeks
Qualitative Analysis of the Efficacy of Probiotic Strains in the Prevention of Antibiotic-Associated Diarrhea.
Dose: None
vs: None
Outcome: None
效果: None
None
研究人群: None
Review
Clostridium difficile Colitis Prevention and Treatment.
Dose: None
vs: None
Outcome: Diarrhea outcomes
效果: None
None
研究人群: None
Systematic Review
n=228
Strain-Specificity and Disease-Specificity of Probiotic Efficacy: A Systematic Review and Meta-Analysis.
Dose: None
vs: None
Outcome: Diarrhea outcomes
效果: None
None
研究人群: None
Review
Probiotics in Gastroenterology: How Pro Is the Evidence in Adults?
Dose: None
vs: None
Outcome: GI condition outcomes (C. diff, AAD, H. pylori)
效果: None
None
研究人群: Adults with GI conditions
Key Statistics
6
研究数量
3000
受试者
↑
Positive
B
等级
Referenced Papers
The evidence for probiotics in the treatment of digestive disorders in the pediatric population.
Review
Journal of gastroenterology …
2025
10 次引用
Advances in experimental …
2024
2 次引用
Cureus
2023
5 次引用
Advances in experimental …
2019
17 次引用
Frontiers in medicine
2018
450 次引用
Pharmacological research
2018
132 次引用
The American journal …
2018
46 次引用
World journal of …
2017
68 次引用
Journal of pediatric …
2016
233 次引用
Clinical and experimental …
2016
82 次引用
Open forum infectious …
2016
58 次引用
Antibiotics (Basel, Switzerland)
2015
104 次引用
Bugs and Guts: Practical Applications of Probiotics for Gastrointestinal Disorders in Children.
Review
Nutrition in clinical …
2015
31 次引用
The American journal …
2012
104 次引用
Saccharomyces boulardii and antibiotic-associated diarrhea: effectiveness of prophylactic use.
Other
The American journal …
2012
5 次引用
Journal of clinical …
2011
432 次引用
Probiotics.
Review
American journal of …
2010
Current opinion in …
2009
82 次引用
The American journal …
2006
918 次引用
Probiotics for the prevention of antibiotic-associated diarrhea and Clostridium difficile diarrhea.
Review
Journal of clinical …
2006
112 次引用
Medical science monitor …
2006
The American journal …
2001
648 次引用
International journal of …
2000
181 次引用
Clinical infectious diseases …
1998
346 次引用
Anaerobe
1997
40 次引用
Gastroenterology
1989
418 次引用
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
常用剂量
- general:
- 250-500 mg/day (equivalent to 5-10 billion CFU)
- aadprevention:
- 500 mg/day (start with antibiotic, continue 7 days after)
- cdiffprevention:
- 500 mg twice daily as adjunct to standard therapy
- travelersdiarrhea:
- 250-500 mg/day starting 5 days before travel
上限： Well-tolerated up to 1,000 mg/day in clinical trials
研究中使用的剂量
| 剂量 | 持续时间 | 效果 | N |
|---|---|---|---|
| None | -- | Mixed | -- |
| None | -- | Positive | -- |
| None | 520 weeks | Positive | -- |
| None | -- | Mixed | -- |
| None | -- | Mixed | 228 |
| None | -- | Mixed | -- |
| None | -- | Mixed | -- |
| None | -- | Mixed | -- |
最佳服用时间： Can be taken with or without food; space 2 hours from antifungals
Safety & Side Effects
已报告的副作用
- ⚠ Mild gas and bloating
- ⚠ Rare: fungemia in critically ill patients with central venous catheters
- ⚠ Thirst (yeast may increase water requirements)
- ⚠ Very rare: potential environmental contamination risk in ICU settings
已知相互作用
- ● Antifungal medications (may kill S. boulardii, reducing effectiveness)
- ● Monoamine oxidase inhibitors (S. boulardii contains tyramine)
- ● Immunosuppressants (theoretical risk of fungemia in immunocompromised patients)
可耐受最高摄入量： Well-tolerated up to 1,000 mg/day in clinical trials
在开始服用任何补充剂之前，请务必咨询您的医疗保健提供者。
Frequently Asked Questions
Does Saccharomyces boulardii help with 艰难梭菌感染（CDI）?
Based on 6 studies with 3,000 participants, there is moderate evidence from clinical studies that Saccharomyces boulardii may support 艰难梭菌感染（CDI） management. Our evidence grade is B (Good Evidence).
How much Saccharomyces boulardii should I take for 艰难梭菌感染（CDI）?
Studies have used various dosages. A commonly studied range is 250-500 mg/day (equivalent to 5-10 billion CFU). Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Saccharomyces boulardii?
Reported side effects may include Mild gas and bloating, Rare: fungemia in critically ill patients with central venous catheters, Thirst (yeast may increase water requirements), Very rare: potential environmental contamination risk in ICU settings. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Saccharomyces boulardii and 艰难梭菌感染（CDI）?
We rate the evidence as Grade B (Good Evidence). This rating is based on 6 peer-reviewed studies with 3,000 total participants. The overall direction of effect is positive.
Related Evidence
Saccharomyces boulardii 用于其他健康状况
References
- [1] Kok-Ann Gwee et al.. J Gastroenterol Hepatol. 2025. The evidence for probiotics in the treatment of digestive disorders in the pediatric population. doi:10.1111/jgh.16809 PubMed
- [2] Elvira Ingrid Levy et al.. Adv Exp Med Biol. 2024. Clostridioides difficile Infections: Prevention and Treatment Strategies. doi:10.1007/978-3-031-58572-2_11 PubMed
- [3] Nyier W Doar et al.. Cureus. 2023. Qualitative Analysis of the Efficacy of Probiotic Strains in the Prevention of Antibiotic-Associated Diarrhea. doi:10.7759/cureus.40261 PubMed
- [4] Meltem Dinleyici et al.. Adv Exp Med Biol. 2019. Clostridium difficile Colitis Prevention and Treatment. doi:10.1007/5584_2018_322 PubMed
- [5] Lynne V McFarland et al.. Front Med (Lausanne). 2018. Strain-Specificity and Disease-Specificity of Probiotic Efficacy: A Systematic Review and Meta-Analysis. doi:10.3389/fmed.2018.00124 PubMed
- [6] Cecilia Mantegazza et al.. Pharmacol Res. 2018. Probiotics and antibiotic-associated diarrhea in children: A review and new evidence on Lactobacillus rhamnosus GG during and after antibiotic treatment. doi:10.1016/j.phrs.2017.08.001 PubMed
- [7] Ronald L Koretz. Am J Gastroenterol. 2018. Probiotics in Gastroenterology: How Pro Is the Evidence in Adults? doi:10.1038/s41395-018-0138-0 PubMed
- [8] Donald Cameron et al.. World J Gastroenterol. 2017. Probiotics for gastrointestinal disorders: Proposed recommendations for children of the Asia-Pacific region. doi:10.3748/wjg.v23.i45.7952 PubMed
- [9] Hania Szajewska et al.. J Pediatr Gastroenterol Nutr. 2016. Probiotics for the Prevention of Antibiotic-Associated Diarrhea in Children. doi:10.1097/MPG.0000000000001081 PubMed
- [10] Heike Stier et al.. Clin Exp Gastroenterol. 2016. Influence of Saccharomyces boulardii CNCM I-745on the gut-associated immune system. doi:10.2147/CEG.S111003 PubMed
- [11] Stephan Ehrhardt et al.. Open Forum Infect Dis. 2016. Saccharomyces boulardii to Prevent Antibiotic-Associated Diarrhea: A Randomized, Double-Masked, Placebo-Controlled Trial. doi:10.1093/ofid/ofw011 PubMed
- [12] Lynne V McFarland. Antibiotics (Basel). 2015. Probiotics for the Primary and Secondary Prevention of C. difficile Infections: A Meta-analysis and Systematic Review. doi:10.3390/antibiotics4020160 PubMed
- [13] Danielle Barnes et al.. Nutr Clin Pract. 2015. Bugs and Guts: Practical Applications of Probiotics for Gastrointestinal Disorders in Children. doi:10.1177/0884533615610081 PubMed
- [14] Pietro Pozzoni et al.. Am J Gastroenterol. 2012. Saccharomyces boulardii for the prevention of antibiotic-associated diarrhea in adult hospitalized patients: a single-center, randomized, double-blind, placebo-controlled trial. doi:10.1038/ajg.2012.56 PubMed
- [15] Maria Assunta Zocco et al.. Am J Gastroenterol. 2012. Saccharomyces boulardii and antibiotic-associated diarrhea: effectiveness of prophylactic use. doi:10.1038/ajg.2012.222 PubMed
- [16] Stefano Guandalini. J Clin Gastroenterol. 2011. Probiotics for prevention and treatment of diarrhea. doi:10.1097/MCG.0b013e3182257e98 PubMed
- [17] Nancy Toedter Williams. Am J Health Syst Pharm. 2010. Probiotics. doi:10.2146/ajhp090168 PubMed
- [18] Alfredo Guarino et al.. Curr Opin Gastroenterol. 2009. Probiotics as prevention and treatment for diarrhea. doi:10.1097/MOG.0b013e32831b4455 PubMed
- [19] Lynne V McFarland. Am J Gastroenterol. 2006. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. doi:10.1111/j.1572-0241.2006.00465.x PubMed
- [20] Jeffry A Katz. J Clin Gastroenterol. 2006. Probiotics for the prevention of antibiotic-associated diarrhea and Clostridium difficile diarrhea. doi:10.1097/00004836-200603000-00017 PubMed
- [21] Mehmet Can et al.. Med Sci Monit. 2006. Prophylactic Saccharomyces boulardii in the prevention of antibiotic-associated diarrhea: a prospective study. PubMed
- [22] P R Marteau et al.. Am J Clin Nutr. 2001. Protection from gastrointestinal diseases with the use of probiotics. doi:10.1093/ajcn/73.2.430s PubMed
- [23] E Bergogne-Bérézin. Int J Antimicrob Agents. 2000. Treatment and prevention of antibiotic associated diarrhea. doi:10.1016/s0924-8579(00)00293-4 PubMed
- [24] C Högenauer et al.. Clin Infect Dis. 1998. Mechanisms and management of antibiotic-associated diarrhea. doi:10.1086/514958 PubMed
- [25] L V McFarland et al.. Anaerobe. 1997. Pharmaceutical probiotics for the treatment of anaerobic and other infections. doi:10.1006/anae.1996.0062 PubMed
- [26] C M Surawicz et al.. Gastroenterology. 1989. Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii: a prospective study. doi:10.1016/0016-5085(89)91613-2 PubMed
FDA 免责声明: 这些声明未经美国食品药品监督管理局（FDA）评估。本网站上的产品和信息无意用于诊断、治疗、治愈或预防任何疾病。所展示的证据等级基于我们对已发表的同行评审研究的分析，不构成医疗建议。在开始任何补充剂方案之前，请务必咨询您的医疗保健提供者。